A prospective survey of atrial fibrillation management in Iran: Baseline results of the Iranian Registry of Atrial Fibrillation (IRAF)

Heidarali, Mona; Bakhshandeh, Hooman; Golpira, Reza; Fazelifar, Amirfarjam; Alizadeh-Diz, Abolfath; Emkanjoo, Zahra; Madadi, Shabnam; Kamali, Farzad; Maleki, Majid; Lip, Gregory Y.H.; Haghjoo, Majid

doi:10.1111/ijcp.14313

Cited by 2 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In familial cases, nearly 1 in 4 patients has a first-degree relative who suffers from AF [ 12 ]. According to the Iranian Registry of Atrial Fibrillation, history of AF in a first-degree relative is positive in 15.3% of the Iranian AF population [ 7 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Whole-exome sequencing reveals a rare missense variant in DTNA in an Iranian pedigree with early-onset atrial fibrillation

Malakootian

Jalilian

Kalayinia

et al. 2022

BMC Cardiovasc Disord

Self Cite

View full text Add to dashboard Cite

Atrial fibrillation (AF) is a morbid and heritable irregular cardiac rhythm that affects about 2%–3% of the population. Patients with early-onset AF have a strong genetic association with the disease; nonetheless, the exact underlying mechanisms need clarification. We herein present our evaluation of a 2-generation Iranian pedigree with early-onset AF. Whole-exome sequencing was applied to elucidate the genetic predisposition. Direct DNA sequencing was utilized to confirm and screen the variants in the proband and his available family members. The pathogenicity of the identified nucleotide variations was scrutinized via either segregation analysis in the family or in silico predictive software. The comprehensive variant analysis revealed a missense variant (c.G681C, p.E227D, rs1477078144) in the human α-dystrobrevin gene (DTNA), which is rare in genetic databases. Most in silico analyses have predicted this variant as a disease-causing variant, and the variant is co-segregated with the disease phenotype in the family. Previous studies have demonstrated the association between the DTNA gene and left ventricular noncompaction cardiomyopathy. Taken together, we provide the first evidence of an association between a nucleotide variation in the DTNA gene and early-onset AF in an Iranian family. However, the genetic testing of AF in the Iranian population is still limited. This finding not only further confirms the significant role of genetics in the incidence of early-onset AF but also expands the spectrum of the gene variations that lead to AF. Additionally, it may have further implications for the treatment and prevention of AF.

show abstract

Section: Introductionmentioning

confidence: 99%

Whole-exome sequencing reveals a rare missense variant in DTNA in an Iranian pedigree with early-onset atrial fibrillation

Malakootian

Jalilian

Kalayinia

et al. 2022

BMC Cardiovasc Disord

Self Cite

View full text Add to dashboard Cite

show abstract

Cost-effectiveness analysis of anticoagulation options for non-valvular atrial fibrillation in Iran

Rezaei,

Bavandpour,

Mobinizadeh

et al. 2024

BMC Res Notes

View full text Add to dashboard Cite

Background Atrial fibrillation (AF) imposes a substantial economic and clinical burden, particularly in developing countries like Iran. This study aimed to evaluate the cost-effectiveness of anticoagulation options for non-valvular atrial fibrillation (NVAF) in Iran. Methods We conducted a cost-effectiveness analysis comparing warfarin, apixaban, dabigatran 110 mg, dabigatran 150 mg, and rivaroxaban for NVAF patients from the Iranian payer’s perspective. A Markov model with a lifetime horizon was used to estimate costs and quality-adjusted life years (QALYs). The model incorporated clinical event rates, case-fatality rates, and utility values. Uncertainty was assessed using deterministic sensitivity analysis and probabilistic sensitivity analysis. Results Among the interventions, warfarin had the lowest cost ($1,755) but apixaban resulted in the highest QALYs (7.33). Apixaban was the most cost-effective strategy with an incremental cost-effectiveness ratio (ICER) of $2,026 per QALY gained compared to warfarin. Apixaban dominated other treatments, with lower costs and higher QALYs. Probabilistic sensitivity analysis indicated that at Iran’s willingness-to-pay threshold of $4,387 per QALY gained, apixaban had a high probability of being cost-effective (88.2%). Conclusion Our study provides strong evidence for healthcare decision-makers in Iran, showing that apixaban is a cost-effective treatment for NVAF, potentially enhancing patient outcomes and optimizing healthcare expenditures. Supplementary Information The online version contains supplementary material available at 10.1186/s13104-024-07004-2.

show abstract

A prospective survey of atrial fibrillation management in Iran: Baseline results of the Iranian Registry of Atrial Fibrillation (IRAF)

Cited by 2 publications

References 36 publications

Whole-exome sequencing reveals a rare missense variant in DTNA in an Iranian pedigree with early-onset atrial fibrillation

Whole-exome sequencing reveals a rare missense variant in DTNA in an Iranian pedigree with early-onset atrial fibrillation

Cost-effectiveness analysis of anticoagulation options for non-valvular atrial fibrillation in Iran

Contact Info

Product

Resources

About